Nexell Therapeutics Inc.

Baxter International Inc.

Other

Baxter Healthcare Inc.

Stephen L Smith

James G Bender

Dennis E Van Epps

Kristen L Unverzagt

Phillip B Maples

Maureen F Loudovaris

Susan M Maciukas

Xiaoying Qiao

Lecon Woo

Sidney T Smith

David V Bacehowski

Larry A Rosenbaum

William Kolanko

Ryan W Johnson

Mark C Olson

James Bender

Michael T K Ling

Michael T Ling

Jeffrey A Martinson

Maureen Loudovaris

Orrin D Mitsven, Jr

A multi-layer, flexible, gas-permeable film (,) suitable for forming a cell culture container (,), the film (,) comprising a first layer (,) composed of a polystyrene having a thickness within the range of 0.0001 inches to about 0.0010 inches and, a second layer (,) adhered to the first layer (,) composed of a polyolefin having a thickness within the range of 0.004 inches to about 0.015 inches.

Multilayer gas-permeable container for the culture of adherent and non-adherent cells

A composition comprising genetically altered human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% human myeloblasts and promyelocytes, which have been derived from neutrophil progenitor cells obtained from peripheral blood, bone marrow or cord blood, and less than about 5% colony forming units (CFU) of at least about 50 cells is provided. An alternative composition comprising genetically altered human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% CD15+CD11b- cells and less than about 5% colony forming units (CFU) of at least about 50 cells also is provided, wherein at least about 60% of the CD15+CD11b- cells are myeloblasts and promyelocytes.

In vitro-derived genetically altered human neutrophil precursor cells

Provided are serum-free, animal protein-free media formulations to be used in conjunction with hematopoietic growth factors for the in vitro growth of human neutrophil and megakaryocyte precursors. The medium contains a base medium, corticosteroid, transferrin, insulin, cholesterol, ethanolamine, and human albumin. Also provided are methods for preparing serum-free, animal protein-free suspensions of human hematopoietic precursor cells wherein the cellular component contains at least about 16% neutrophil precursors and at least about 1% megakaryocyte precursors. Serum-free, animal protein-free suspensions of human hematopoietic cells are provided wherein the cellular component comprises at least about 30%, preferably greater than 60% neutrophil precursors. The neutrophil precursors are comprised of blast cells, promyclocytes, neutrophilic myelocytes, and neutrophilic metamyelocytes. Serum-free, animal protein-free cells suspensions are provided wherein the cellular component comprises at least about 3%, preferably greater than 8% megakaryocyte precursors. Also provided are serum-free, animal protein free cell suspensions wherein the cellular component comprises colony-forming cells and cluster-forming cells.

Preparation of serum-free suspensions of human hematopoietic cells or

The invention provides a method of treating a patient having a reduced population of neutrophils following a myeloablative cancer treatment such as high dose chemotherapy. Following myeloablative therapy, a cell composition of at least 25% neutrophil precursors, i.e. promyelocytes, myelocytes, and metamyelocytes, is administered to the patient. Thereafter, the neutrophil precursors differentiate rapidly in vivo to replenish the supply of mature neutrophils for fighting infection. The method is used to reduce the neutropenic window between the time of myeloablative therapy and the time required for infused stem cells to proliferate and differentiate into mature neutrophils.

Infusion of neutrophil precursors for treatment of neutropenia

The present invention provides a composition of human neutrophil precursor cells having at least 37% myeloblasts and promyeloblasts. Also provided are hematopoietic cell suspensions that have human neutrophil precursor cells and at least one hematopoietic growth factor.

In-vitro-derived human neutrophil precursor cells

A multi-layer, flexible, gas-permeable film (10) suitable for forming a cell culture container (20), the film (10) comprising a first layer (12) composed of a polystyrene having a thickness within the range of 0.0001 inches to about 0.0010 inches and, a second layer (14) adhered to the first layer (12) composed of a polymer material having a thickness within the range of 0.004 inches to about 0.025 inches.

Multilayer gas-permeable container for the culture of adherent and

A suspension comprising human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% human myeloblasts and promyeclocytes, which have been derived from neutrophis progenitor cells obtained from peripheral blood, bone marrow or cord blood, and less than about 5% colony forming units (CFU) of at least about 50 cells is provided. An alternative suspension comprising human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% CD15+CD11b- cells and less than about 5% colony forming units (CFU) of at least about 50 cells also is provided, wherein at least about 60% of the CD15+CD11b- cells are myeloblasts and promyelocytes. The suspensions of the invention are useful in methods for increasing neutrophil populations in a patient having a reduced populations of neutrophils.

Method for increasing neutrophil populations using in vitro-derived

A composition of human neutrophil precursor cells is disclosed wherein at least 16% of the cells are human myeloblasts and promyelocytes. The myeloblasts and promyelocytes are derived from human neutrophil progenitor cells that were obtained from peripheral blood, bone marrow or cord blood. The neutrophil precursor cells contain less than 5% colony forming units. Also disclosed are human neutrophil precursor cells made up of about 16% CD15+CD11b- cells and less than 5% colony forming units and methods of preparing these compositions.

Method for the preparation of in vitro-derived human neutrophil

The present invention provides an apparatus for holding and carrying a plurality of flexible medical containers. The carrier has a rack having a plurality of plates positioned in parallel spaced relation, the plates defining a chamber between each pair of adjacent plates. A plurality of spacer assemblies each extend through the rack to connect the plates and to maintain their spaced relationship. The spacer assemblies are spaced along marginal edges of the rack to define two opposed end walls, a bottom, and an opening to the rack to allow access to each of the chambers. A flange extends from one of the plates and has a hole that allows the carrier to be suspended. The invention further provides for a system for transferring fluids and a method for mixing solutions using the carrier.

Growing community of inventors

Arlington Heights, IL, United States of America

Stephen L Smith